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Echinococcus 
multilocularis in
Northern Hungary 
To the Editor: Echinococcus mul-
tilocularis infection is one of the most
dangerous zoonoses in the Northern
Hemisphere and causes more human
death than rabies in Europe. Recent
data indicate that E. multilocularis
infection is spreading geographically
and is being transmitted at an increas-
ing rate in Europe (Figure). Since
1995, the parasite has been found in
Poland, the Czech Republic, the
Slovak Republic, Belarus, Hungary,
and Romania; infections in humans
have been increasing in frequency in
central eastern Europe since the late
1990s (1–4). Since the 1990s, similar
infection trends in foxes and humans
have been observed in central western
European countries, including eastern
Austria, northern Germany, Denmark,
the Netherlands, Luxembourg, and
Belgium (1,2,5). Despite the increas-
ing prevalence of E. multilocularis
infection in foxes, the number of
human cases did not vary in the his-
torically known area (eastern France,
Switzerland, southern Germany, and
western Austria) during the 1990s (1),
probably because of increased public
awareness and control measures. In
our previous study (2), the parasite
was detected only in foxes in the
Hungarian-Slovak border area in
northeastern Hungary. In the current
study, we found the parasite distrib-
uted along the watershed area of the
River Danube in northern Hungary.
In the second half of 2003, car-
casses of red foxes were sent to the
Central Veterinary Institute in
Budapest for examination in connec-
tion with the rabies immunization and
control program in seven counties
(Vas, Gyor-Sopron, Komárom-
Esztergom, Pest, Nógrád, Heves, and
Borsod-Abaúj-Zemplén) that bor-
dered or were near the border of
Austria and the Slovak Republic.
These foxes were included in the cur-
rent study. Methods of transporting
and storing the carcasses, examining
the intestinal tracts, and identifying
parasites have been described previ-
ously (2).
Of 150 foxes examined, 19 ani-
mals from four counties (Gyor-
Sopron, Komárom-Esztergom, Pest,
and Nógrád) harbored 2, 3, 4, 6, 7, 14,
22, 31, 51, 54, 114, 130, 200, 250,
300, 400, 800, and 1,300, and 5,500
mature worms of Echinococcus. On
the basis of the most important mor-
phometric guidelines and the results
of the species-specific polymerase
chain reaction (PCR) assay, the para-
sites were identified as E. multilocu-
laris. The examined foxes were found
from 5 to 70 km from the known
endemic areas of the Slovak Republic,
Austria, and Hungary, and from 5 to
50 km from the northern border of the
country. On the basis of this informa-
tion and the previous study (2), the
overall prevalence rate of infection
was 16% (24/156) in the five northern
counties of Hungary (Gyor-Sopron
30%, Nógrád 26%, Komárom-
Esztergom 7%, Pest 6%, and Borsod-
Abaúj-Zemplén 5%). This prevalence
rate is similar to those observed in
Poland, Belgium, and the Slovak
Republic in recent years. In these
countries, a total of 30 human cases
have been reported since 1995 (3–6).
In Germany, infected foxes were
more frequently found near water (7),
which indicates a water-related natu-
ral cycle of the parasite. The spatial
aggregation analysis of the parasite in
intermediate hosts demonstrated that
areas with humid conditions are at
high risk for human exposure (8). In
Europe, the most important water-
related intermediate host of E. multi-
locularis is the water vole (Arvicola
terrestris) (9). The prevalence of E.
multilocularis in water voles can be as
high as 39% in disease-endemic areas
(10). Areas with high water-vole den-
sities yielded a 10-fold higher risk for
alveolar echinococcosis in humans
compared to areas with low densities
(10). These data indicate that water
voles may play an important role in
the epidemiology of E. multilocularis.
All infected foxes included in this and
the previous study (2) were found
near permanent natural waters, i.e., in
those areas where water vole popula-
tions exist, such as Lake Ferto, the
River Danube, the River Ipoly, the
River Rába, and several streams con-
nected to the watershed area of the
River Danube. E. multilocularis
might have spread in the northern part
of Hungary along the watershed area
of the River Danube, coming from the
known disease-endemic areas of
Austria and the Slovak Republic.
Similar spreading of the parasite
along waterways was also observed in
the Slovak Republic (11).
In the historically known E. multi-
locularis–endemic mountain areas,
both fossorial and aquatic water voles
exist (12). The density of these popu-
lations can be 10-fold greater than that
of aquatic populations in other
European countries (12). On the basis
of the long incubation period of the
parasite in humans (5–15 years) and
the dates of the first human cases
reported outside the historically
known area (Figure), foxes might
have reached the population density
needed (13) to maintain the parasite
cycle in low water-vole density areas
in Europe from the 1980s (Figure).
Although the parasite crossed the bor-
der of several countries that surround-
ed the known area, further spreading
was not observed in those countries
where A. terrestris is an endangered
species (the Netherlands, northern
Italy) or where water voles are absent
from the fauna (western and southern
France) (12).
The River Danube and several
small streams crossing Budapest, the
capital of Hungary with a population
of 2 million, create ideal circum-
stances for urbanization of the life
cycle of a parasite that involves water
voles and red foxes. Urbanization of
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the life cycle of E. multilocularis was
recently observed in Prague, the capi-
tal of the Czech Republic with a pop-
ulation of 1 million and similar hydro-
graphic features (14); therefore,
occurrences of this zoonosis should
be continuously monitored in
Budapest. Further studies are neces-
sary to monitor the possible spread of
the parasite in other regions that are
thought to be currently free of the
infection.
The regulatory, veterinary, and
public health authorities of the
European Union mobilized consider-
able financial and human resources to
control rabies and paid less attention
to alveolar echinococcosis in the
1990s, although incidence data indi-
cate that alveolar echinococcosis is
increasing and became an emerging
infectious disease in Europe. In the
Directive 2003/99/EC of the
European Parliament and of the
Council repealing Council Directive
92/117/EEC, echinococcosis has been
added to the list of zoonoses to be
monitored in the European Union
countries. Effective methods to con-
trol E. multilocularis are unavailable;
however, the zoonosis should be mon-
itored and evaluated, and develop-
ment of control programs should be
intensified.
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Figure. Distribution of Echinococcus multilocularis in Europe (1,2,4, this study). Black
areas: Infection was reported in men, foxes and or rodents. Dark gray areas: Infection was
described only in foxes and or rodents. Light gray areas: Only human cases were noted.
White areas: E. multilocularis free territories. Question marks: The presence or appear-
ance of the parasite is projected. Note: The prevalence of infection in foxes is similar in
the majority of the affected countries.LETTERS
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Antimicrobial
Resistance in
Campylobacter
To the Editor: We wish to rectify
several errors in our commentary,
Antibiotics in Animal Feed and
Spread of Resistant Campylobacter
from Poultry to Humans (1). The flu-
oroquinolone enrofloxacin was
approved in 1996 for therapeutic use
by addition to drinking water upon the
decision of a licensed veterinarian
“for the control of mortality in chick-
ens associated with Escherichia coli
organisms and control of mortality in
turkeys associated with E. coli and
Pasteurella multocida organisms” (2).
This therapeutic use was withdrawn
(3) but is now under appeal. Initial
approval and subsequent efforts to
withdraw use of enrofloxacin in the
United States parallel the earlier trend
in Europe and specifically Denmark,
where the use of antimicrobial agents
as growth promoters has been banned
(4). 
Enrofloxacin is not approved for
prophylactic or growth promotion use
in poultry feed as stated in our com-
mentary and in the first section of the
flowchart (1). However, when
enrofloxacin is added to the drinking
water of poultry, large numbers of
both ill and healthy animals are
exposed to the agent (5). Although
extra-label use of enrofloxacin is pro-
hibited, microbiologic culture of
either of the cited bacteria is not
required before administration (2).
Despite the restrictions on
enrofloxacin use, emergence of fluo-
roquinolone-resistant Campylobacter
species, with poultry as an important
source, has been documented in the
United States (5,6). Thus the decision
to withdraw therapeutic use of
enrofloxacin (3) was warranted.
Therefore, our conclusion remains:
use of enrofloxacin in poultry materi-
ally contributed to increase in human
infection by fluoroquinolone-resistant
Campylobacter species. Given the
above, our commentary should have
been entitled Use of Antibiotics in the
Poultry Industry and Spread of
Resistant Campylobacter to Humans.
We regret the errors and hope we have
clarified this issue. 
Nicole M. Iovine* 
and Martin J. Blaser*†
*New York University School of Medicine,
New York, New York, USA; †New York
Harbor Department of Veterans Affairs
Medical Center, New York, New York, USA
References:
1. Iovine N, Blaser MJ. Antibiotics in animal
feed and spread of resistant Campylobacter
from poultry to humans. Emerg Infect Dis.
2004;10:1158–9.
2. Sundlof S. Enrofloxacin for Poultry;
Opportunity for Hearing.  Department of
Health and Human Services, Food and Drug
Administration, Center for Veterinary
Medicine. Fed Register. 2000;65:64954–65.
3. Davidson D. In the matter of enrofloxacin
for poultry: withdrawal of approval of
Bayer Corporation’s new animal drug
application 1 (NADA) 140-828 (Baytril).
FDA Docket No 00N-1571 2004.
4. DANMAP 2002. Use of antimicrobial
agents and occurrence of antimicrobial
resistance in bacteria from food animals,
foods and humans in Denmark.
Copenhagen Danish Zoonosis Center,
Danish Veterinary Institute. 2003.
5. Gupta A, Nelson JM, Barrett TJ, Tauxe RV,
Rossiter SP, Friedman CR, et al.
Antimicrobial resistance among
Campylobacter strains, United States,
1997–2001. Emerg Infect Dis.
2004;10:1102–9.
6. Smith KE, Besser JM, Hedberg CW, Leano
FT, Bender JB, Wicklund JH, et al.
Quinolone-resistant  Campylobacter jejuni
infections in Minnesota, 1992-1998.
Investigation Team. N Engl J Med.
1999;340:1525−32.
Address for correspondence: Martin J. Blaser,
Department of Medicine, NYU School of
Medicine, 550 First Avenue, OBV-606, New
York, NY 10016, USA; fax: 212-263-3969;
email: martin.blaser@med.nyu.edu
1346 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 10, No. 7, July 2004
Search past issues of EID at www.cdc.gov/eid